With a lifetime 1 in 4 risk of its development ( 1 ), atrial fibrillation (AF) continues to be the most common cardiac arrhythmia that impairs quality of life and contributes to increased susceptibility to heart failure, hospitalization, stroke, and mortality, costing society more than $15 billion annually ( 2,3 ). With the rapid increase in the number of elderly patients ( 4 ) and cardiovascular comorbidities ( 5 ), a 6-fold increase in the prevalence of AF (from 2.3 million to 15.9 million) is projected ( 6 ), highlighting the magnitude of the problem and the far-reaching implications that the epidemic of AF will have on the health and economics of the country. Thus, an urgent need exists to better understand clinical factors and the basic biology that predispose to AF and its progression and associated complications so that effective preventive strategies can be implemented to reduce the burden of AF on society. AF is a heterogeneous disorder with variable etiology, clinical profile, and natural history ( 2 ). From a clinical perspective, AF has been broadly classified as paroxysmal, persistent (or long-lasting), and permanent, depending on the duration of symptoms and its propensity to terminate by
/lp/elsevier/progression-of-paroxysmal-to-persistent-atrial-fibrillation-i5OBHPwBqe